Ocular Therapeutix™ Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
BTIG Downgrades Ocular Therapeutix (OCUL) to Neutral
May 5, 2017 2:35 PM EDTBTIG downgraded Ocular Therapeutix (NASDAQ: OCUL) from Buy to Neutral. Analyst Dane Leone thinks there is risk of a delay in the current PDUFA date for Dextenza.
For an analyst ratings summary and ratings history on Ocular Therapeutix... More
Ocular Therapeutix (OCUL) Misses Q1 EPS by 10c
May 5, 2017 7:33 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.58), $0.10 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $475 thousand versus the consensus estimate of $470 thousand.
This is an important time for Ocular Therapeutix as we approach the PDUFA target action... More



